%0 Journal Article
%T KRAS  mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patients
%A Alejandro Mart¨ªnez
%A Clara Mayo
%A Cristina Teixid¨®
%A Daniela Morales-Espinosa
%A Maria de los Llanos Gil
%A M¨®nica Garz¨®n
%A Rafael Rosell
%A Santiago Viteri
%A Sergi Villatoro
%J SCIE-indexed Journal
%D 2016
%X Lung cancer is the most common cancer and the first cause of cancer deaths worldwide (1). NSCLC is the predominant subtype of lung cancer, being adenocarcinoma the most common histology. Unfortunately, almost half of NSCLC patients are diagnosed at advanced stage and have poor prognosis and limited options for treatment, traditionally restricted to chemotherapy (2). However, in recent years, the identification of prognostic and predictive biomarkers has led to improvements in outcome and has set allowed the application of personalized medicine approaches in NSCLC patients. More than 50% of advanced NSCLC patients harbor a driver genetic alteration that, if targetable, changes the therapeutic panorama (3). For this reason, implementing resources for quick, cost-effective, multiplex detection of alterations has recently gained importance for cancer diagnostics
%U http://tlcr.amegroups.com/article/view/10204/8674